PO.ET08.02 · 实验与分子治疗
Radiopharmacuetical Platforms for Theranostic Precision Oncology
- 5807 5807 Synergistic integration of nanobodies and a specialized linker library: A novel radionuclide drug conjugate (RDC) platform paving the way for next-generation radiotherapeutics with optimal druggability and therapeutic index Chong Liu, Zengyan Mu, Sipeng Li, Qingsong Wu, Yajun Sun, Paul H. Song, Gang Qin
- 5810 5810 [ 212 Pb]Pb-AG1206, A novel fibroblast activation protein-targeted radioligand therapy demonstrated excellent efficacy and safety profile Xin Gan, Tao Robert Wu, Miaomiao Song, Shaohua Xu, Guiyu Liu, Vivi Yang, Jinpeng Liu, Xuefei Li, Hu Li, Zhen Cheng, Maijing Liao
-
- 5812 5812 Preclinical evaluation of [177Lu]Lu-PSMA-617 and [225Ac]Ac-PSMA-617 in mice bearing castration-resistant prostate adenocarcinoma patient-derived xenografts Denis Beckford-Vera, Jaeho Lee, Kyle Monger, Erin Kosmowski, Kayla Cotton, Sebastian Brabetz, Markus Hippich, Sarah Maenhout, Paul Heverly, Maria Mancini
-
-
-
-
- 5817 5817 A novel NTSR1-targeting alpha radiotherapeutic SKL35501 demonstrating potent anti-tumor efficacy in HCT116 colorectal tumor model Jungtae Na, Taeyun Lee, Seona Jeon, Hyunseok Lee, Sunghak Lee, Sungwan Hwang, Jungshin Park
-
- 5819 5819 PD-L1 targeted radiotherapy can reduce tumor burden and delay tumor growth in a mouse model of triple-negative breast cancer Jonathan Moye, Hailey Houson, Sharmila Sridhar, Sherin James, Jason M. Warram, Suzanne E. Lapi, Anna G. Sorace
- 5820 5820 Biodistribution analysis of Leutetium-177 radiopharmaceuticals in mammary, prostate, and glioblastoma models using Alpha-SPECT Mini and gamma counts Kathryn R. Meshaw, William F. Durham, Karsten E. Fynboe, Tyler Rowe, Jacob C. Hauser, Joseph P. Kolb, Kenneth A. Meshaw, Stephanie M. Fogerson, Beth A. Hollister
- 5821 5821 Utilize a soluble T-cell receptor TCR targeting tumor intracellular antigen PRAME to develop therapeutic and radioactive diagnostic agents for PRAME-positive tumors Yujun Huang, Xiao Liang, Yajuan Xue
- 5822 5822 Efficacy of targeted radionuclide therapy Using 131 I-FAPi dimers labeled via tetrazine ligation in a human glioblastoma xenograft model Umberto Maria Battisti, Marcel Martin, Vladimir Shalgunov, Filipe Elvas, Alan Miranda, Andreas Jensen, Matthias Herth
- 5824 5824 First target disclosure for the preclinical development of ATNM-400, a first-in-class actinium-225 radioconjugate with pan-tumor efficacy in solid tumors Amanda S. Chin, Sumit Mukherjee, Jason Li, Karina Peregrina, Debbie Lewis, Le-Cun Xu, Dhiren Patel, Madhuri Vusirikala, Monideepa Roy, Adeela Kamal
-
-
- 5827 5827 Actimab-A, a CD33-targeted actinium-225 radioconjugate, drives mutation-agnostic anti-leukemic activity and synergizes with standard therapies in AML through transcriptional reprogramming Amanda S. Chin, Merve Sahin, Jason Li, Le-Cun Xu, Monideepa Roy, Madhuri Vusirikala, Kaitlyn H. Ko, Wenbin Xiao, Adeela Kamal, Sheng F. Cai
